[HTML][HTML] Early relapse in first-line follicular lymphoma: a review of the clinical implications and available mitigation and management strategies
TD Rodgers, C Casulo, F Boissard, A Launonen… - Oncology and …, 2021 - Springer
Chemoimmunotherapy with rituximab (R-chemo) or obinutuzumab (G-chemo) is standard of
care for patients with previously untreated symptomatic or high-tumor-burden follicular …
care for patients with previously untreated symptomatic or high-tumor-burden follicular …
[HTML][HTML] Myeloablative chemotherapy for chemo-sensitive recurrent follicular lymphoma: potential benefit in second relapse
S Montoto, J Matthews, P Greaves, D Lillington… - …, 2013 - ncbi.nlm.nih.gov
Defining the role of high-dose therapy with autologous stem cell rescue in the therapeutic
algorithm of follicular lymphoma remains a major challenge. In contrast to the acknowledged …
algorithm of follicular lymphoma remains a major challenge. In contrast to the acknowledged …
Maintenance rituximab after CVP results in superior clinical outcome in advanced follicular lymphoma (FL): results of the E1496 phase III trial from the Eastern …
E1496 is a phase III trial designed to evaluate the ability of 2 years (yr) of maintenance
rituximab (MR) to prolong progression-free survival (PFS) after CVP (cyclophosphamide 1 …
rituximab (MR) to prolong progression-free survival (PFS) after CVP (cyclophosphamide 1 …
Follicular lymphoma in the United States: first report of the national LymphoCare study
JW Friedberg, MD Taylor, JR Cerhan… - Journal of Clinical …, 2009 - ascopubs.org
Purpose Optimal therapy of follicular lymphoma (FL) is not defined. We analyzed a large
prospective cohort study to identify current demographics and patterns of care of FL in the …
prospective cohort study to identify current demographics and patterns of care of FL in the …
[HTML][HTML] Survival after progression in patients with follicular lymphoma: analysis of prognostic factors
S Montoto, A Lopez-Guillermo, A Ferrer, M Camós… - Annals of oncology, 2002 - Elsevier
Background The purpose of this study was to identify prognostic parameters for patients with
follicular lymphoma (FL) in first progression/relapse. These would be useful for selection of …
follicular lymphoma (FL) in first progression/relapse. These would be useful for selection of …
[HTML][HTML] A comparison of the effectiveness of first-line chemoimmunotherapy regimens for follicular lymphoma (FL) used in the United States
L Nastoupil, R Sinha, M Byrtek, M Taylor, JR Cerhan… - Blood, 2011 - Elsevier
Abstract Abstract 97 Background: There is no consensus or standard of care for front-line
therapy for FL as demonstrated by our initial publication of the National LymphoCare Study …
therapy for FL as demonstrated by our initial publication of the National LymphoCare Study …
High rate of clinical and molecular remissions in follicular lymphoma patients receiving high-dose sequential chemotherapy and autografting at diagnosis: a …
M Ladetto, P Corradini, S Vallet… - Blood, The Journal …, 2002 - ashpublications.org
Single-center experiences have shown that intensified treatments with autologous
transplantation are a promising therapeutic strategy for patients with high-risk follicle-center …
transplantation are a promising therapeutic strategy for patients with high-risk follicle-center …
[HTML][HTML] High complete response rates with pembrolizumab in combination with rituximab in patients with relapsed follicular lymphoma: results of an open-label, phase …
L Nastoupil, JR Westin, NH Fowler, MA Fanale… - Blood, 2017 - Elsevier
Background: Follicular lymphoma (FL) tumors are infiltrated with antitumor T cells, however,
their function is impaired by immune checkpoints such as PD-1/PD-ligand pathway. Blocking …
their function is impaired by immune checkpoints such as PD-1/PD-ligand pathway. Blocking …
Long-term follow-up of the RESORT study (E4402): a randomized phase III comparison of two different rituximab dosing strategies for low–tumor burden follicular …
BS Kahl, OA Jegede, C Peterson… - Journal of Clinical …, 2024 - ascopubs.org
Clinical trials frequently include multiple end points that mature at different times. The initial
report, typically based on the primary end point, may be published when key planned co …
report, typically based on the primary end point, may be published when key planned co …
Follicular lymphoma: have we made any progress?
SJ Horning - Annals of oncology, 2000 - Elsevier
Follicular lymphomas are characterized by relatively long median survivals and a
continuous pattern of relapse. The heterogeneity in these diseases is increasingly …
continuous pattern of relapse. The heterogeneity in these diseases is increasingly …